Looks like you’re on the UK site. Choose another location to see content specific to your location
Allergan wins NICE approval for IBS-D therapy Truberzi
Allergan's Truberzi medication has been granted approval by the National Institute for Health and Care Excellence (NICE).
The drug, also known as eluxadoline, is used to treat irritable bowel syndrome and diarrhoea (IBS-D) and will be made available to patients who have not responded to or are unable to take other medications.
It works differently to existing treatments in that it binds to specific receptors in the digestive system, which slows the movement of food through the gut, helping to relieve stomach cramps and the need to go to the toilet.
Director of the centre for health technology evaluation at NICE Professor Carole Longson said the body is "pleased to be able to recommend" Truberzi.
"IBS-D can significantly impact a person’s quality of life, sometimes leading to anxiety and affecting their daily activities," she observed.
As many as 20 per cent of the UK population suffers from IBS, with a third of these affected by IBS-D.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard